Minor Applications
HEALTH TECHNOLOGYVASOPRESSINSAMBONG 250 MG TABLETVARENICLINENICOTINE REPLACEMENT THERAPY2.5% PERITONEAL DIALYSIS SOLUTION0.1% SODIUM HYALURONATE (15 ML)
PROPONENTDOH Disease Prevention and Control BureauPhilippine Institute of Traditional and Alternative Health Care (PITAHC)DPCB – Lifestyle-Related Diseases DivisionDPCB – Lifestyle-Related Diseases DivisionPhilippine General Hospital, National Kidney and Transplant InstituteAsian Eyes Optical
TOPIC NOMINATION
APPRAISAL AND RECOMMENDATION
APPEALS ON PRELIMINARY HTAC RECOMMENDATION
FINAL RECOMMENDATION28 February 202214 January 2022
17 May 2021
17 May 2021
17 February 2021
10 March 2021

DECISION OF THE SECRETARY OF HEALTH02 March 202214 January 2022
17 May 2021
17 May 2021
19 February 2021
10 March 2021

DISSEMINATIONLink to HTAC RecommendationLink to HTAC RecommendationLink to issuanceLink to issuanceLink to IssuanceLink to Issuance
Urgent HTA Track
HEALTH TECHNOLOGYORAL PRE-EXPOSURE PROPHYLAXIS (PREP)TENOFOVIR/LAMIVUDINE/DOLUTEGRAVIRDOLUTEGRAVIRINACTIVATED POLIOVIRUS VACCINE (IPV) (TRANSITION FROM ONE- TO TWO-DOSE)10- AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINES (PCV) (REASSESSMENT)
PROPONENTNational AIDS and STI Prevention and Control Program – Philippines (NASPCP)National AIDS and STI Prevention and Control Program – Philippines (NASPCP)National AIDS and STI Prevention and Control Program – Philippines (NASPCP)DOH National Immunization ProgramDOH National Immunization Program
TOPIC NOMINATION
TOPIC PRIORITIZATION
SCOPING AND PROTOCOL DEVELOPMENT
ASSESSMENT
EVIDENCE APPRAISAL
PRELIMINARY RECOMMENDATION
APPEALS
RESOLUTION
FINAL RECOMMENDATION17 December 201721 September 202113 July 202114 August 2020
DECISION OF THE SECRETARY OF HEALTH18 January 202228 September 202110 September 202114 August 2020
DISSEMINATIONLink to issuance
Link to Evidence Summary
Link to Evidence Summary and IssuanceLink to issuance
Link to Evidence Summary
Link to Issuance
Link to Evidence Summary
General HTA Track
Name of DrugStatus
Abiraterone for adult men with prostate cancerOn-going assessment
Aflibercept for wet age-related macular degenerationFor External Commissioning
Cerebrolysin for patients with acute ischemic stroke, dementia and traumatic brain injuryOn-going assessment
Citicoline for acute and recovery phase of cerebral infarction (e.g., ischemia due to stroke)On-going assessment
Dabigatran for myocardial infarction with atrial fibrillationOn-going assessment
Dapagliflozin (5mg/10 mg tablet) for adult patients with Type 2 Diabetes Mellitus patients inadequately controlled on metformin monotherapyDapagliflozinOn-going assessment
Dexamethasone for diabetic macular edemaFor External Commissioning
Eltrombopag olamine in the treatment of refractory thrombocytopenia among patients with chronic immune thrombocytopenia (ITP)On-going assessment
Enzalutamide (40mg soft gel capsule) for adult men with metastatic castration-resistant prostate cancer (mCRPC)On-going assessment
Eribulin for Metastatic Soft Tissue Sarcoma (mSTS)For finalization of recommendation after appeals
Insulin aspart (100 U/mL) for Type 1 and Type 2 Diabetes MellitusFor External Commissioning
Insulin detemir (100 U/mL) for Type 1 and Type 2 Diabetes MellitusFor finalization of recommendation after appeals
Insulin glargine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes MellitusFor finalization of recommendation after appeals
Insulin glulisine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes MellitusFor External Commissioning
Insulin lispro (Mix – P 814 3ml pre-filled pen (100 U/mL); Insulin Lispro 100 Units/mL, 10 ml vial)For External Commissioning
Ivabradine for the treatment of stable angina pectoris among adult patients with coronary artery diseaseOn-going assessment
Nilotinib as first-line treatment for Chronic Phase-Chronic Myeloid LeukemiaOn-going assessment
Pazopanib as treatment for Renal Cell CarcinomaFor External Commissioning
Pertuzumab for HER2+ Breast CancerFor finalization of recommendation after appeals
Ranibizumab for visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO)For External Commissioning
Rituximab SC for Non-Hodgkin’s LymphomaFor finalization of recommendation after appeals
Rivaroxaban for myocardial infarction with atrial fibrillationOn-going assessment
Sitagliptin for Uncontrolled Type 2 Diabetes MellitusFor External Commissioning
Sunitinib for Renal Cell CarcinomaFor External Commissioning
TACE with Mitomycin C for patients with non-resectable Hepatocellular CarcinomaFor External Commissioning
Ticagrelor for the prevention of thrombotic events among patients with Acute Coronary SyndromeOn-going assessment
Tirofiban HCl for treatment of unstable angina or non-Q wave myocardial infarctionFor External Commissioning
Zoledronic acid for prevention of skeletal-related events in cancer patientsOn-going assessment
Expedited HTA Track (COVID-19 Vaccines)
PROCESSPEDIA VACCINATION 5 to 11 YRS OLDPEDIA VACCINATION 12 to 17 YRS OLDBOOSTER AND ADDITIONAL DOSEPFIZERASTRAZENECASINOVACSPUTNIK VJOHNSON & JOHNSON
MODERNACOVOVAXCOVAXINSINOPHARM
EUA Approval
Data Extraction and Synthesis
HTAC Recommendation
Decision of Secretary of Health
DisseminationLink to Evidence SummaryLink to Evidence SummaryLink to Evidence SummaryVersion 1Version 1Link to Evidence SummaryVersion 1Version 1Link to Evidence SummaryLink to Evidence SummaryLink to Evidence SummaryLink to Evidence Summary
Version 2Version 2Link to Evidence SummaryVersion 2Version 2
Version 3
Expedited HTA Track (COVID-19 Investigational Drugs)
HEALTH TECHNOLOGYCASIRIVIMAB+INDEVIMABDEXAMETHASONEFAVIPIRAVIRREMDESIVIRBARICITINIBTOCILUZIMAB
PROPONENTDisease Prevention and Control Bureau (DPCB)Philippine Academy of OphthalmologyDOH Disease Prevention and Control BureauDOH Disease Prevention and Control BureauDOH Disease Prevention and Control BureauDOH Disease Prevention and Control Bureau
TOPIC NOMINATION
TOPIC PRIORITIZATION
ASSESSMENT
RECOMMENDATION
DECISION OF THE SECRETARY OF HEALTH
DISSEMINATIONLink to HTAC RecommendationLink to Signed Endorsement Letter and Evidence SummaryDexamethasone
Link to issuance
Dexamethasone
Link to issuance
Dexamethasone
Link to issuance
Dexamethasone
Link to issuance
Expedited HTA Track (COVID-19 Diagnostics)
HEALTH TECHNOLOGYSELF ADMINISTERED ANTIGEN TEST KITS (SAAGT)RAPID ANTIGEN TEST KITS (APRIL 2021 UPDATE)RAPID ANTIGEN TEST KITS (SEPTEMBER 2021 UPDATE)RT-PCR TESTING (APRIL 2021 UPDATE)
PROPONENTNational Task Force (NTF)PHST, (HTAC-initiated)PHST, (HTAC-initiated)SOH, (HTAC-initiated)
TOPIC NOMINATION
TOPIC PRIORITIZATION
ASSESSMENT
RECOMMENDATION30 April 202027 September 202130 April 2021
DECISION OF THE SECRETARY OF HEALTH
DISSEMINATIONLink to Signed Endorsement Letter
Link to Evidence Summary
Link to Signed Endorsement Letter
Link to Evidence Summary
Link to Signed Endorsement Letter
Link to Evidence Summary